SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material
SEC Accession No. 0001193125-17-131741
Filing Date
2017-04-21
Accepted
2017-04-21 11:04:32
Documents
9
Filing Date Changed
2017-04-21
Effectiveness Date
2017-04-21

Document Format Files

Seq Description Document Type Size
1 DEFA14A d296773ddefa14a.htm DEFA14A 30678
2 GRAPHIC g296773g34q84.jpg GRAPHIC 2520
3 GRAPHIC g296773g40x44.jpg GRAPHIC 14090
4 GRAPHIC g296773g58r98.jpg GRAPHIC 8442
5 GRAPHIC g296773g65f29.jpg GRAPHIC 7668
6 GRAPHIC g296773g65o52.jpg GRAPHIC 2316
7 GRAPHIC g296773g83s26.jpg GRAPHIC 9262
8 GRAPHIC g296773g87k92.jpg GRAPHIC 3810
9 GRAPHIC g296773g93m58.jpg GRAPHIC 3737
  Complete submission text file 0001193125-17-131741.txt   104146
Mailing Address 11080 CIRCLEPOINT ROAD SUITE 140 WESTMINSTER CO 80020
Business Address 11080 CIRCLEPOINT ROAD SUITE 140 WESTMINSTER CO 80020 720-940-2200
ARCA biopharma, Inc. (Filer) CIK: 0000907654 (see all company filings)

IRS No.: 363855489 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 000-22873 | Film No.: 17774607
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
Assistant Director 1